Skip to main content
Log in

LUNG CANCER

Liquid biopsy for early stage lung cancer moves ever closer

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

Lung cancer screening is currently based only on low-dose CT scans; however, novel, more accessible methods that might improve uptake and adherence are eagerly awaited. New liquid biopsy approaches promise to revolutionize cancer screening. Herein, we discuss the opportunities and challenges associated with two such novel assays.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: Liquid biopsy for early lung cancer detection.

References

  1. Shieh, Y. & Bohnenkamp, M. Low-dose CT scan for lung cancer screening: clinical and coding considerations. Chest 152, 204–209 (2017).

    Article  Google Scholar 

  2. Okereke, I. C., Nishi, S., Zhou, J. & Goodwin, J. S. Trends in lung cancer screening in the United States, 2016–2017. J. Thorac. Dis. 11, 873–881 (2019).

    Article  Google Scholar 

  3. Rolfo, C. et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J. Thorac. Oncol. 13, 1248–1268 (2018).

    Article  Google Scholar 

  4. Abbosh, C., Birkbak, N. J. & Swanton, C. Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection. Nat. Rev. Clin. Oncol. 15, 577–586 (2018).

    Article  CAS  Google Scholar 

  5. Russo, A. et al. Liquid biopsy tracking of lung tumor evolutions over time. Expert Rev. Mol. Diagn. 19, 1099–1108 (2019).

    Article  CAS  Google Scholar 

  6. Chabon, J. J. et al. Integrating genomic features for non-invasive early lung cancer detection. Nature 580, 245–251 (2020).

    Article  CAS  Google Scholar 

  7. Liu, M. C. et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. 31, 745–759 (2020).

    Article  Google Scholar 

  8. Lennon, A. M. et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science https://doi.org/10.1126/science.abb9601 (2020).

    Article  PubMed  Google Scholar 

  9. Sozzi, G. et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J. Clin. Oncol. 32, 768–773 (2014).

    Article  Google Scholar 

  10. Zhang, L. et al. A high-performing plasma metabolite panel for early-stage lung cancer detection. Cancers (Basel) 12, E622 (2020).

    Article  Google Scholar 

Download references

Acknowledgements

We thank Umberto Malapelle and Diego de Miguel Perez for their helpful suggestions during manuscript preparation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christian Rolfo.

Ethics declarations

Competing interests

C.R. has received speakers’ bureau from AstraZeneca and MSD, a research grant from the Lung Cancer Research Foundation–Pfizer, and research support from Guardant Health and Biomark; has an advisory board role with ARCHER, Inivata and Merck Serono; and has consulted for Mylan and Oncopass. A.R declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rolfo, C., Russo, A. Liquid biopsy for early stage lung cancer moves ever closer. Nat Rev Clin Oncol 17, 523–524 (2020). https://doi.org/10.1038/s41571-020-0393-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-020-0393-z

  • Springer Nature Limited

This article is cited by

Navigation